BPG is committed to discovery and dissemination of knowledge
Minireviews
Copyright: ©Author(s) 2026. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution-NonCommercial (CC BY-NC 4.0) license. No commercial re-use. See permissions. Published by Baishideng Publishing Group Inc.
World J Diabetes. Aug 15, 2026; 17(8): 119203
Published online Aug 15, 2026. doi: 10.4239/wjd.119203
Severe insulin-deficient diabetes: Updated review of epidemiology, biology, and clinical implications
Yara S Beyh, K M Venkat Narayan, Ram Jagannathan
Yara S Beyh, K M Venkat Narayan, Ram Jagannathan, Emory Global Diabetes Research Center, Hubert Department of Global Health, Rollins School of Public Health, Emory University, Atlanta, GA 30322, United States
K M Venkat Narayan, Department of Endocrinology, Emory School of Medicine, Emory University, Atlanta, GA 30322, United States
Author contributions: Narayan KMV conceptualized the idea of the review; Beyh YS conducted the research and wrote the initial manuscript; Beyh YS and Jagannathan R edited the manuscript; all authors have read and approved the final manuscript.
AI contribution statement: AI tools were not used in the production of this manuscript.
Supported by National Heart, Lung, and Blood Institute, No. P01HL154996; and National Institute of Diabetes and Digestive and Kidney Diseases, No. R01-DK139632.
Conflict-of-interest statement: The authors declare that they have no conflict of interest.
Corresponding author: Yara S Beyh, PhD, Post Doctoral Researcher, Emory Global Diabetes Research Center, Hubert Department of Global Health, Rollins School of Public Health, Emory University, 1518 Clifton Rd NE, Atlanta, GA 30322, United States. ybeyh@emory.edu
Received: January 21, 2026
Revised: May 22, 2026
Accepted: July 14, 2026
Published online: August 15, 2026
Processing time: 196 Days and 8.8 Hours
Core Tip

Core Tip: Severe insulin-deficient diabetes (SIDD) is a reproducible, non-autoimmune subtype of type 2 diabetes defined by profound β-cell dysfunction, marked hyperglycemia, and relatively lower body mass index. This review synthesizes global evidence showing that SIDD carries disproportionate microvascular risk particularly retinopathy and often requires early treatment intensification with frequent insulin use. A key innovation is highlighting population-specific subtype distributions, with insulin-deficient phenotypes more common in South Asians and linked to emerging signals for higher mortality and excess life-years lost. We integrate genetic and multi-omic insights implicating β-cell stress pathways and outline priorities for electronic health record-ready classification and subtype-guided trials.

Write to the Help Desk